Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

IMiD immunomodulatory compounds block C/EBP  translation through eIF4E down-regulation resulting in inhibition of MM

(2011) S. Li et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

(2011) Lars Anders et al.   CANCER CELL

Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors

(2010) J. Bretz et al.   BLOOD

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

CDK Inhibitor p18INK4c Is a Downstream Target of GATA3 and Restrains Mammary Luminal Progenitor Cell Proliferation and Tumorigenesis

(2009) Xin-Hai Pei et al.   CANCER CELL

Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment

(2009) Zachary T. Schafer et al.   NATURE

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development

(2008) Ruprecht Wiedemeyer et al.   CANCER CELL

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications

(2008) P. E. Leone et al.   CLINICAL CANCER RESEARCH

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

CDK inhibitors in cancer therapy: what is next?

(2007) Marcos Malumbres et al.   TRENDS IN PHARMACOLOGICAL SCIENCES